

When citing an abstract from the 2017 annual meeting please use the format below.

[Authors]. [Abstract Title]. Program No. XXX.XX. 2017 Neuroscience Meeting Planner.
Washington, DC: Society for Neuroscience, 2017. Online.

2017 Copyright by the Society for Neuroscience all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.

Basic-Translational-Clinical Roundtables

268. Hearing Loss, Brain Function, and Healthy Aging

Location: 206

Time: Monday, November 13, 2017, 8:30 AM - 11:00 AM

Description: Strategies to optimize healthy aging are imperative. From 2000 to 2050, the proportion of the world's population over age 60 will double from 11 percent to 22 percent, making this population larger than that of children under 14 for the first time in history. This session will discuss what constitutes healthy aging, explore hearing loss as an exemplar of a potential intervention target, and discuss the current and future role of neuroprostheses for hearing.

Organizer/Moderator: F. R. LIN;
Johns Hopkins Univ., Baltimore, MD

Disclosure: F.R. Lin: Consultant to Cochlear Ltd.

Speaker: L. Ferrucci;
National Institute on Aging, Baltimore, MD.

Disclosure: L. Ferrucci: None.

Speaker: A. Sharma;
Univ Colorado, Boulder, Boulder, CO.

Disclosure: A. Sharma: None.

Speaker: B. Wilson;
Duke University, Durham, NC.

Disclosure: B. Wilson: Other; MED-EL GmbH.

Basic-Translational-Clinical Roundtables

445. Advances and Challenges in Deep Brain Stimulation

Location: 206

Time: Tuesday, November 14, 2017, 8:30 AM - 11:00 AM

Description: More than 160,000 patients have received deep brain stimulation (DBS), mostly for Parkinson's disease. This session will provide an overview of new DBS applications and discuss some of the emerging mechanisms and biological effects being discovered. The overall aim is to

identify areas that require further exploration to optimize DBS therapy and to develop novel directions for this technology.

Organizer/Moderator: *A. M. LOZANO;
Univ. of Toronto, Toronto, ON, Canada

Disclosure: A.M. Lozano: Functional Neuromodulation, Medtronic, St Jude, Boston Scientific, Insightec.

Speaker: C. C. McIntyre;
Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH.

Disclosure: C.C. McIntyre: E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); Surgical Information Sciences, Neuros Medical, Autonomic Technologies, Cardionomic, Enspire DBS. F. Consulting Fees (e.g., advisory boards); Boston Scientific Neuromodulation.

Speaker: P. Brown;
Department of Clinical Neurology, University of Oxford, Oxford, UNITED KINGDOM.

Disclosure: P. Brown: None.

Speaker: P. L. Strick;
University of Pittsburgh School of Medicine, Pittsburgh, PA.

Disclosure: P.L. Strick: None.

Basic-Translational-Clinical Roundtables

634. Emerging Neuroimaging Biomarkers for Schizophrenia

Location: 206

Time: Wednesday, November 15, 2017, 8:30 AM - 11:00 AM

Description: This session will introduce the development of neuroimaging biomarkers for schizophrenia. It will cover diagnostic and subtyping biomarkers, biomarkers of genetic risk for schizophrenia, neurochemical and molecular markers of pathophysiology, and pathophysiological biomarkers related to illness progression and treatment.

Organizer/Moderator: *J. KRYSTAL;
Yale Sch. of Med., New Haven, CT

Disclosure: J. Krystal: Yale School of Medicine, VA CT Healthcare System (part-time), AstraZeneca Pharmaceuticals provides the drug, Saracatinib, for research related to NIAAA grant "Center for Translational Neuroscience of Alcoholism [CTNA-4], Pfizer Pharmaceuticals

provides an investigational drug, PF-03463275, for research related to NIH grant “Translational Neuroscience Optimization of GlyT1 Inhibitor”, ArRETT Neuroscience, Inc. - Stock, Biohaven Pharmaceuticals Medical Sciences - Stock and Stock Options, Blackthorn Therapeutics, Inc. - Stock Options, Luc Therapeutics, Inc., Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948. September 5, 1995, Vladimir, Coric, Krystal, John H, Sanacora, Gerard – Glutamate Modulating Agents in the Treatment of Mental Disorders US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014., Charney D, Krystal JH, Manji H, Matthew S, Zarate C., - Intranasal Administration of Ketamine to Treat Depression United States Application No. 14/197,767 filed on March 5, 2014; United States applica, Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Department of Veterans Affairs “Methods for Treating Suicidal Ideation”, Patent Application No. 14/197.767 filed on March 5, 2014 by Y, Arias A, Petrakis I, Krystal JH. – Composition and methods to treat addiction. Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research, Chekroud, A., Gueorguieva, R., & Krystal, JH. “Treatment Selection for Major Depressive Disorder” [filing date 3rd June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Ya, Gihyun, Yoon, Petrakis I, Krystal JH – Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552, filed on Jan, Biohaven Pharmaceuticals - SAB, Blackthorn Therapeutics, Inc. - SAB, Lohocla Research Corporation - SAB, LUC Therapeutics, Inc. - SAB, Prizer Pharmaceuticals, TRImaran Pharma - SAB, AstraZeneca Pharmaceuticals, Biogen, Biomedisyn Corporaton, Forum Pharmaceuticals, Janssen Research & Development, L.E.K. Consulting, Otsuka America Pharmaceutical, Inc., S K Life Science, Spring Care, Inc., Sunovion Pharmaceuticals, Inc., Takeda Industries, Taisho Pharmaceutical Co., Ltd.

Speaker: A. Anticevic;

Psychiatry, Yale University, New Haven, CT.

Disclosure: A. Anticevic: None.

Speaker: A. Abi-Dargham;

Psychiatry, Stony Brook University, Stony Brook, NY.

Disclosure: A. Abi-Dargham: None.

Speaker: C. E. Bearden;

UCLA, Los Angeles, CA.

Disclosure: C.E. Bearden: None.